Stenabolic (SR9009) 10 mg – 100 Capsules

Biochem Stenabolic (SR9009) 10 mg – 100 Capsules | Experimental REV-ERB Nuclear Receptor Modulator

Biochem Stenabolic (SR9009) 10 mg – 100 Capsules is an oral capsule product containing stenabolic, also known as SR9009, a synthetic experimental compound investigated for its interactions with REV-ERB nuclear receptors and their roles in circadian rhythm regulation, metabolism, and cellular physiology.

This product contains 10 mg of stenabolic per capsule, with 100 capsules per package, representing 1,000 mg (1 gram) of stenabolic per package, based on the stated formulation.

Stenabolic belongs to a class of experimental compounds originally described as REV-ERB receptor agonists.

REV-ERB receptors, including REV-ERBα and REV-ERBβ, are nuclear receptors involved in the regulation of circadian rhythms, metabolic gene expression, inflammatory signaling, and cellular energy balance.

REV-ERBα is encoded by the NR1D1 gene, while REV-ERBβ is encoded by the NR1D2 gene.

These receptors participate in molecular feedback mechanisms that help coordinate biological processes with the body's internal circadian clock.

SR9009 was developed as a chemical tool for investigating REV-ERB-associated biological pathways.

Early laboratory research suggested that SR9009 could influence gene expression associated with circadian regulation, glucose metabolism, lipid metabolism, and skeletal muscle physiology.

Preclinical animal studies also investigated relationships between SR9009 exposure, energy expenditure, metabolic regulation, and exercise-related outcomes.

However, animal and laboratory findings do not establish that stenabolic improves endurance, increases fat loss, or enhances athletic performance in humans.

An important limitation of the available evidence is that subsequent research has questioned whether all biological effects attributed to SR9009 are mediated directly through REV-ERB receptors.

Experimental studies have reported effects that may occur independently of REV-ERBα and REV-ERBβ, indicating that SR9009 should not be regarded as a fully validated receptor-selective compound.

Stenabolic is frequently discussed alongside selective androgen receptor modulators (SARMs), but stenabolic is not a SARM.

Unlike ostarine (MK-2866), ligandrol (LGD-4033), and andarine (S-4), SR9009 is not primarily classified as an androgen receptor modulator.

It is also pharmacologically different from cardarine (GW-501516), which is a PPARδ agonist, and ibutamoren (MK-677), which is a ghrelin receptor agonist.

SR9009 has been studied predominantly in laboratory and animal research.

There is no adequate body of controlled human clinical evidence establishing its pharmacokinetics, safety, effectiveness, or appropriate therapeutic use.

Its oral bioavailability has been reported as poor in preclinical research, making extrapolation from experimental exposure conditions to commercial oral capsules particularly uncertain.

Claims that stenabolic reliably increases metabolic rate, improves sleep, regulates circadian rhythms, enhances endurance, or accelerates fat loss in humans are not supported by adequate clinical evidence.

Potential toxicological effects, drug interactions, reproductive effects, cardiovascular consequences, and long-term safety remain insufficiently characterized.

Stenabolic has no established approved therapeutic indication.

SR9009 is prohibited in competitive sport under World Anti-Doping Agency rules as a metabolic modulator.

The Biochem brand name does not independently establish pharmaceutical approval, manufacturing quality, analytical purity, or clinical suitability.

1. Was Developed to Investigate REV-ERB Nuclear Receptors

Stenabolic was originally described as a synthetic agonist of REV-ERBα and REV-ERBβ.

These nuclear receptors participate in transcriptional networks involved in circadian rhythms, metabolism, and cellular homeostasis.

REV-ERB receptors generally function as transcriptional repressors through interactions with regulatory proteins and chromatin-associated mechanisms.

SR9009 was investigated as a chemical tool for modifying these signaling pathways.

However, later studies identified biological effects that may not depend on REV-ERB receptor activity, limiting confidence in its original target-selectivity claims.

2. Has Been Investigated in Circadian Rhythm Research

REV-ERB receptors are important components of the molecular circadian clock.

Circadian regulation influences sleep-wake patterns, hormone secretion, metabolic activity, and other physiological processes.

Experimental studies have investigated how modulation of REV-ERB-associated pathways affects circadian gene expression.

These findings do not establish that oral stenabolic capsules improve sleep quality, correct circadian disorders, or produce predictable changes in human sleep-wake cycles.

3. Has Been Investigated in Metabolic Regulation

REV-ERB-associated signaling participates in the regulation of metabolic gene expression.

Laboratory and animal studies involving SR9009 have examined pathways associated with glucose metabolism, lipid metabolism, and cellular energy balance.

Some preclinical investigations reported changes in metabolic measurements following experimental exposure.

However, these observations cannot be interpreted as proof of clinically meaningful weight loss, improved insulin sensitivity, or metabolic health benefits in humans.

4. Has Been Investigated in Skeletal Muscle Physiology

Experimental research has examined relationships between REV-ERB signaling, mitochondrial function, and skeletal muscle metabolism.

Some animal studies involving SR9009 reported changes in exercise-related measurements.

However, the findings remain preclinical and may be influenced by experimental conditions, exposure methods, and effects unrelated to REV-ERB receptors.

There is insufficient evidence to establish that stenabolic increases endurance, strength, or exercise capacity in humans.

5. Is Pharmacologically Different From SARMs

Stenabolic is frequently grouped with SARMs in online product discussions.

However, SARMs primarily interact with androgen receptors, whereas SR9009 was developed to investigate REV-ERB-associated signaling.

Stenabolic is therefore more accurately described as an experimental REV-ERB-related nuclear receptor modulator rather than a selective androgen receptor modulator.

Its nonsteroidal classification does not establish safety or exclude endocrine and metabolic risks.

6. Has Important Pharmacokinetic and Mechanistic Limitations

Preclinical investigations have reported limitations in the oral bioavailability of SR9009.

This is particularly relevant when evaluating claims about oral capsule formulations.

There is insufficient human pharmacokinetic evidence to establish reliable absorption, systemic exposure, elimination half-life, or dose-response relationships.

Furthermore, published studies have questioned the assumption that all observed effects of SR9009 are mediated through REV-ERB receptors.

The pharmacological properties of a particular commercial formulation cannot be established solely from its stated capsule strength.

7. Has No Established Human Safety Profile

SR9009 has not undergone sufficient controlled human clinical investigation to establish an acceptable safety profile.

Potential concerns include unknown effects on cardiovascular physiology, metabolic regulation, liver function, reproductive physiology, and other organ systems.

The absence of well-characterized human adverse-event data should not be interpreted as evidence of safety.

Stenabolic has no established approved therapeutic indication for weight loss, athletic performance, endurance, metabolic disorders, circadian rhythm disorders, or any other medical condition.

The 10 mg capsule strength describes the product presentation and does not establish a medically validated or safe human dose.

Step 1 – Oral Capsule Administration

Stenabolic is presented in oral capsule form.

Following ingestion, the capsule would need to release its contents within the gastrointestinal tract.

The dissolution and absorption characteristics of this specific Biochem formulation have not been independently established.

Step 2 – Gastrointestinal Absorption and Systemic Exposure

For an orally administered compound to produce systemic effects, sufficient quantities must be absorbed into circulation.

Preclinical studies have identified poor oral bioavailability as a limitation of SR9009.

The systemic exposure achievable from the requested Biochem capsule formulation is unknown.

Step 3 – Potential Interaction With Cellular Signaling Pathways

SR9009 was originally developed to investigate REV-ERB-associated transcriptional signaling.

However, experimental evidence indicates that some effects may occur independently of REV-ERB receptors.

Consequently, its cellular pharmacology should not be described as exclusively REV-ERB-mediated.

Step 4 – Experimental Modulation of Gene Expression

Laboratory studies have reported changes in gene expression and cellular responses associated with metabolic and circadian pathways.

These effects depend on experimental conditions and may involve multiple molecular mechanisms.

Such findings do not independently establish therapeutic or performance-related benefits in humans.

Step 5 – Metabolism and Elimination

Following systemic exposure, SR9009 may undergo metabolic processing and elimination.

Its human metabolic pathways, elimination half-life, and potential interactions with other compounds have not been adequately established.

The pharmacokinetic characteristics of this specific Biochem capsule formulation remain unverified.

The Biochem Stenabolic 10 mg capsule presentation includes the following characteristics:

• Stenabolic (SR9009) as the stated active compound.
• 10 mg per capsule.
• 100 capsules per package.
• 1,000 mg total stated active ingredient content.
• Oral capsule presentation.
• Synthetic nonsteroidal chemical structure.
• Experimental nuclear receptor modulator classification.
• Originally proposed REV-ERB agonist activity.
• Investigation of REV-ERBα-associated signaling.
• Investigation of REV-ERBβ-associated signaling.
• Experimental research involving circadian biology.
• Experimental research involving metabolic gene expression.
• Preclinical investigation of glucose and lipid metabolism.
• Preclinical investigation of skeletal muscle physiology.
• Animal research involving exercise-related measurements.
• Published evidence of possible REV-ERB-independent biological effects.
• Poor oral bioavailability reported in preclinical research.
• No established human oral bioavailability.
• No validated human therapeutic dosing regimen.
• No established approved human therapeutic indication.
• No demonstrated clinical benefit for endurance or fat loss.
• Inadequately characterized human toxicology.
• Inadequately characterized long-term human safety.
• Prohibited status under WADA rules.
• Capsule excipients requiring confirmation.
• Identity, purity, and content uniformity requiring independent analytical verification.

The precise excipient composition, capsule appearance, manufacturing specifications, purity, and analytical content of Biochem Stenabolic 10 mg have not been independently verified.

The stated package contains 100 capsules of 10 mg each, representing 1,000 mg total stated active ingredient.

This description does not establish regulatory authorization, clinical safety, reliable oral systemic exposure, or suitability for human administration.

United States

Biochem Stenabolic 10mg, Biochem SR9009 10mg, Stenabolic 10mg 100 capsules, SR9009 100 capsules, Stenabolic United States, Stenabolic REV-ERB modulator, SR9009 experimental compound, Stenabolic molecular formula, Stenabolic chemical structure, SR9009 REV-ERB receptor research, Stenabolic pharmacology, Stenabolic preclinical studies, SR9009 circadian rhythm research, Stenabolic metabolic pathways, SR9009 oral bioavailability, Stenabolic safety concerns, SR9009 human clinical evidence, Stenabolic capsule specifications.

Canada

English: Biochem Stenabolic 10mg Canada, SR9009 10mg Canada, Stenabolic 100 capsules, Stenabolic REV-ERB modulator, SR9009 nuclear receptor research, Stenabolic properties, SR9009 pharmacology, Stenabolic molecular structure, SR9009 circadian biology, Stenabolic metabolic research, SR9009 preclinical studies, Stenabolic oral bioavailability, SR9009 safety information, Stenabolic clinical evidence.

French: Biochem Stenabolic 10 mg Canada, SR9009 10 mg, Stenabolic 100 capsules, modulateur expérimental REV-ERB, récepteurs nucléaires REV-ERB, propriétés du stenabolic, pharmacologie du SR9009, structure moléculaire, rythme circadien, régulation métabolique, études précliniques, biodisponibilité orale, mécanismes indépendants de REV-ERB, informations de sécurité, absence de données cliniques suffisantes.

United Kingdom

Biochem Stenabolic 10mg UK, Stenabolic SR9009 UK, Stenabolic 100 capsules, experimental REV-ERB modulator, SR9009 pharmacology, Stenabolic chemical structure, REV-ERBα receptor research, REV-ERBβ receptor research, Stenabolic preclinical studies, SR9009 circadian rhythm, Stenabolic metabolic signaling, SR9009 oral bioavailability, Stenabolic safety profile, limited human clinical evidence.

Germany

Biochem Stenabolic 10 mg Deutschland, Stenabolic SR9009, Stenabolic 100 Kapseln, experimenteller REV-ERB-Modulator, Stenabolic Eigenschaften, SR9009 Wirkungsmechanismus, REV-ERBα Rezeptor, REV-ERBβ Rezeptor, Molekülstruktur, präklinische Studien, zirkadianer Rhythmus, Stoffwechselregulation, orale Bioverfügbarkeit, Sicherheitsinformationen, fehlende klinische Daten.

France

Biochem Stenabolic 10 mg France, Stenabolic SR9009, Stenabolic 100 gélules, modulateur expérimental REV-ERB, propriétés du stenabolic, mécanisme d'action du SR9009, récepteur REV-ERBα, récepteur REV-ERBβ, structure moléculaire, études précliniques, rythme circadien, régulation métabolique, biodisponibilité orale, informations de sécurité, données cliniques insuffisantes.

Spain

Biochem Stenabolic 10 mg España, Stenabolic SR9009, Stenabolic 100 cápsulas, modulador experimental REV-ERB, propiedades del stenabolic, mecanismo de acción del SR9009, receptor REV-ERB alfa, receptor REV-ERB beta, estructura molecular, estudios preclínicos, ritmo circadiano, regulación metabólica, biodisponibilidad oral, información de seguridad, evidencia clínica insuficiente.

Italy

Biochem Stenabolic 10 mg Italia, Stenabolic SR9009, Stenabolic 100 capsule, modulatore sperimentale REV-ERB, proprietà dello stenabolic, meccanismo d'azione SR9009, recettore REV-ERB alfa, recettore REV-ERB beta, struttura molecolare, studi preclinici, ritmo circadiano, regolazione metabolica, biodisponibilità orale, informazioni di sicurezza, dati clinici insufficienti.

Portugal

Biochem Stenabolic 10 mg Portugal, Stenabolic SR9009, Stenabolic 100 cápsulas, modulador experimental REV-ERB, propriedades do stenabolic, mecanismo de ação do SR9009, recetor REV-ERB alfa, recetor REV-ERB beta, estrutura molecular, estudos pré-clínicos, ritmo circadiano, regulação metabólica, biodisponibilidade oral, informações de segurança, evidência clínica insuficiente.

Netherlands

Biochem Stenabolic 10 mg Nederland, Stenabolic SR9009, Stenabolic 100 capsules, experimentele REV-ERB-modulator, eigenschappen van stenabolic, werkingsmechanisme SR9009, REV-ERBα receptor, REV-ERBβ receptor, moleculaire structuur, preklinisch onderzoek, circadiaans ritme, metabole regulatie, orale biologische beschikbaarheid, veiligheidsinformatie, onvoldoende klinische gegevens.

Belgium

Biochem Stenabolic 10 mg België, Stenabolic 10 mg Belgique, Stenabolic SR9009, Stenabolic 100 capsules, experimentele REV-ERB-modulator, modulateur expérimental REV-ERB, eigenschappen van stenabolic, propriétés du stenabolic, REV-ERB receptor, récepteur REV-ERB, preklinisch onderzoek, études précliniques, circadiaans ritme, rythme circadien, orale biologische beschikbaarheid, biodisponibilité orale, veiligheidsinformatie.

Switzerland

Biochem Stenabolic 10 mg Schweiz, Stenabolic 10 mg Suisse, Stenabolic SR9009, Stenabolic 100 Kapseln, Stenabolic 100 gélules, experimenteller REV-ERB-Modulator, modulateur expérimental REV-ERB, REV-ERB Rezeptor, récepteur REV-ERB, präklinische Studien, études précliniques, zirkadianer Rhythmus, rythme circadien, orale Bioverfügbarkeit, biodisponibilité orale, Sicherheitsinformationen.

Austria

Biochem Stenabolic 10 mg Österreich, Stenabolic SR9009, Stenabolic 100 Kapseln, experimenteller REV-ERB-Modulator, Stenabolic Eigenschaften, SR9009 Wirkungsmechanismus, REV-ERBα Rezeptor, REV-ERBβ Rezeptor, Molekülstruktur, präklinische Forschung, zirkadianer Rhythmus, Stoffwechselregulation, orale Bioverfügbarkeit, Sicherheitsinformationen, fehlende klinische Daten.

Sweden

Biochem Stenabolic 10 mg Sverige, Stenabolic SR9009, Stenabolic 100 kapslar, experimentell REV-ERB-modulator, stenabolic egenskaper, SR9009 verkningsmekanism, REV-ERBα receptor, REV-ERBβ receptor, molekylstruktur, prekliniska studier, dygnsrytm, metabol reglering, oral biotillgänglighet, säkerhetsinformation, otillräckliga kliniska data.

Norway

Biochem Stenabolic 10 mg Norge, Stenabolic SR9009, Stenabolic 100 kapsler, eksperimentell REV-ERB-modulator, stenabolic egenskaper, SR9009 virkningsmekanisme, REV-ERBα reseptor, REV-ERBβ reseptor, molekylstruktur, prekliniske studier, døgnrytme, metabolsk regulering, oral biotilgjengelighet, sikkerhetsinformasjon, utilstrekkelige kliniske data.

Denmark

Biochem Stenabolic 10 mg Danmark, Stenabolic SR9009, Stenabolic 100 kapsler, eksperimentel REV-ERB-modulator, stenabolic egenskaber, SR9009 virkningsmekanisme, REV-ERBα receptor, REV-ERBβ receptor, molekylstruktur, prækliniske studier, døgnrytme, metabolisk regulering, oral biotilgængelighed, sikkerhedsinformation, utilstrækkelige kliniske data.

Finland

Biochem Stenabolic 10 mg Suomi, Stenabolic SR9009, Stenabolic 100 kapselia, kokeellinen REV-ERB-modulaattori, stenabolicin ominaisuudet, SR9009 vaikutusmekanismi, REV-ERBα reseptori, REV-ERBβ reseptori, molekyylirakenne, prekliiniset tutkimukset, vuorokausirytmi, aineenvaihdunnan säätely, suun kautta otettavan aineen biologinen hyötyosuus, turvallisuustiedot, riittämätön kliininen näyttö.

Poland

Biochem Stenabolic 10 mg Polska, Stenabolic SR9009, Stenabolic 100 kapsułek, eksperymentalny modulator REV-ERB, właściwości stenabolicu, mechanizm działania SR9009, receptor REV-ERBα, receptor REV-ERBβ, struktura molekularna, badania przedkliniczne, rytm dobowy, regulacja metaboliczna, biodostępność doustna, informacje o bezpieczeństwie, niewystarczające dane kliniczne.

Czech Republic

Biochem Stenabolic 10 mg Česko, Stenabolic SR9009, Stenabolic 100 kapslí, experimentální modulátor REV-ERB, vlastnosti stenabolicu, mechanismus účinku SR9009, receptor REV-ERBα, receptor REV-ERBβ, molekulární struktura, preklinické studie, cirkadiánní rytmus, metabolická regulace, perorální biologická dostupnost, bezpečnostní informace, nedostatečné klinické údaje.

Romania

Biochem Stenabolic 10 mg România, Stenabolic SR9009, Stenabolic 100 capsule, modulator experimental REV-ERB, proprietăți stenabolic, mecanism de acțiune SR9009, receptor REV-ERBα, receptor REV-ERBβ, structură moleculară, studii preclinice, ritm circadian, reglare metabolică, biodisponibilitate orală, informații de siguranță, date clinice insuficiente.

Greece

Biochem Stenabolic 10 mg Ελλάδα, στεναμπολικό SR9009, Stenabolic 100 κάψουλες, πειραματικός τροποποιητής REV-ERB, ιδιότητες στεναμπολικού, μηχανισμός δράσης SR9009, υποδοχέας REV-ERBα, υποδοχέας REV-ERBβ, μοριακή δομή, προκλινικές μελέτες, κιρκάδιος ρυθμός, μεταβολική ρύθμιση, από του στόματος βιοδιαθεσιμότητα, πληροφορίες ασφάλειας, ανεπαρκή κλινικά δεδομένα.

Ireland

Biochem Stenabolic 10mg Ireland, Stenabolic SR9009 Ireland, Stenabolic 100 capsules, experimental REV-ERB modulator, SR9009 pharmacology, Stenabolic molecular structure, REV-ERB receptor research, Stenabolic preclinical studies, SR9009 circadian biology, Stenabolic metabolic signaling, SR9009 oral bioavailability, Stenabolic safety information, insufficient human clinical evidence.

Colombia

Biochem Stenabolic 10 mg Colombia, Stenabolic SR9009 Colombia, Stenabolic 100 cápsulas, stenabolic 10 mg, modulador experimental REV-ERB, propiedades del stenabolic, cómo funciona el SR9009, farmacología del stenabolic, receptor REV-ERB alfa, receptor REV-ERB beta, estructura molecular, estudios preclínicos, ritmo circadiano, regulación metabólica, biodisponibilidad oral, información de seguridad, evidencia clínica insuficiente.

Argentina

Biochem Stenabolic 10 mg Argentina, Stenabolic SR9009 Argentina, Stenabolic 100 cápsulas, stenabolic 10 mg, modulador experimental REV-ERB, propiedades del stenabolic, qué es el SR9009, mecanismo de acción del stenabolic, receptores REV-ERB, estructura molecular, estudios preclínicos, ritmo circadiano, metabolismo celular, biodisponibilidad oral, información de seguridad.

México

Biochem Stenabolic 10 mg México, Stenabolic SR9009 México, Stenabolic 100 cápsulas, stenabolic 10 mg, modulador experimental REV-ERB, propiedades del stenabolic, para qué se investigó el SR9009, cómo funciona el stenabolic, farmacología del SR9009, receptor REV-ERB alfa, estructura molecular, estudios preclínicos, ritmo circadiano, regulación metabólica, biodisponibilidad oral, evidencia clínica insuficiente.

Perú

Biochem Stenabolic 10 mg Perú, Stenabolic SR9009 Perú, Stenabolic 100 cápsulas, stenabolic 10 mg, modulador experimental REV-ERB, propiedades del stenabolic, mecanismo de acción del SR9009, farmacología del stenabolic, receptor REV-ERB alfa, receptor REV-ERB beta, estructura molecular, estudios preclínicos, ritmo circadiano, regulación metabólica, biodisponibilidad oral, información de seguridad.

Venezuela

Biochem Stenabolic 10 mg Venezuela, Stenabolic SR9009 Venezuela, Stenabolic 100 cápsulas, stenabolic 10 mg, modulador experimental REV-ERB, propiedades del stenabolic, qué es el SR9009, cómo actúa el stenabolic, farmacología del SR9009, receptores REV-ERB, estructura molecular, estudios preclínicos, ritmo circadiano, metabolismo celular, biodisponibilidad oral, evidencia clínica insuficiente.

Ecuador

Biochem Stenabolic 10 mg Ecuador, Stenabolic SR9009 Ecuador, Stenabolic 100 cápsulas, stenabolic 10 mg, modulador experimental REV-ERB, propiedades del stenabolic, cómo funciona el SR9009, farmacología del stenabolic, mecanismo de acción, receptor REV-ERB alfa, receptor REV-ERB beta, estructura molecular, estudios preclínicos, ritmo circadiano, regulación metabólica, biodisponibilidad oral, información de seguridad.

Biochem Stenabolic (SR9009) 10mg | 100 Capsules | Experimental REV-ERB Modulator

Learn about Biochem Stenabolic SR9009 10mg, 100 capsules. This product contains stenabolic, an experimental compound investigated in preclinical circadian and metabolic research, with uncertain receptor selectivity, poor reported oral bioavailability, and no established safe human use.

Biochem Stenabolic (SR9009) 10mg | 100 Cápsulas | Modulador Experimental REV-ERB

Conoce Biochem Stenabolic SR9009 10mg, 100 cápsulas. Este producto contiene stenabolic, un compuesto experimental investigado en estudios preclínicos del ritmo circadiano y el metabolismo, con selectividad incierta, baja biodisponibilidad oral y sin uso seguro establecido en humanos.

biochem-stenabolic-sr9009-10mg-100-capsules

biochem-stenabolic-sr9009-10mg-100-capsulas

Biochem Stenabolic SR9009 10mg, 100 oral capsules containing stenabolic, an experimental REV-ERB-related compound associated with preclinical research on circadian regulation, metabolic signaling, and cellular physiology.

Biochem Stenabolic SR9009 10mg, 100 cápsulas orales que contienen stenabolic, un compuesto experimental relacionado con REV-ERB e investigaciones preclínicas sobre regulación circadiana, señalización metabólica y fisiología celular.